Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the Netherlands / NCT05357807
Active, not recruiting Not applicable

Extending and Banding the Roux-en-Y Gastric Bypass

NCT05357807 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Rijnstate Hospital
Phase
Not applicable
Started
2021-03-01
Last updated
2024-06-21

Condition(s) studied

Morbid Obesity

Investigational drug(s) / intervention(s)

Standard RYGBExtended Pouch RYGBBanded extended pouch RYGB

Standard RYGB: Roux-en-Y Gastric bypass

Extended Pouch RYGB: Roux-en-Y gastric bypass with an extended pouch

Banded extended pouch RYGB: Roux-en-Y gastric bypass with a banded extended pouch

Study summary

The Roux-en-Y gastric bypass (RYGB) has proven to be an effective treatment for morbid obesity by reducing weight and comorbidities. Extending the pouch may improve weightloss without the increase of complications. Some patients regain weight after initially good weightloss. Placing a minimizer around the pouch may prevent weight regain.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * All patients who are eligible for a primary RYGB Exclusion Criteria: * Bariatric surgery in medical history * Patients with a language barrier which may affect the compliance with medical advice * Patients with a disease not related to morbid obesity, such as Cushing or drug related. * Chronic bowel disease for example Crohn's disease or colitis Colitis. * Renal impairment (MDRD \<30) * Hepatic dysfunction (liver function twice the normal values) * Pregnancy during follow-up * Patients with treatment-resistant reflux symptoms.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Rijnstate Hospital Arnhem Gelderland
St. Antonius Ziekenhuis Nieuwegein Utrecht
NOK West The Hague Netherlands

More Rijnstate Hospital trials in the Netherlands

The Impact of Optical Coherence Tomography on the Endovascular Treatment Planning of Femoropopliteal Disease Active, not recruiting
Progression Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound Flow Imaging Active, not recruiting
Evaluation of Effectiveness of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy for Treatment of Chemotherapy Induced Peripheral Neuropathy Recruiting
The PREBA Study: Effect of Preoperative Weight Loss With a 14-day Low-calorie Diet on Surgical Procedure and Outcomes in Patients Undergoing RYGB Surgery Active, not recruiting
Tonometry(1) and Duplex Ultrasound(2) to Predict CV Events in to be Treated Patients With an AAA Recruiting

Other trials for the same condition

The PREBA Study: Effect of Preoperative Weight Loss With a 14-day Low-calorie Diet on Surgical Procedure and Outcomes in Patients Undergoing RYGB Surgery Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05357807 on ClinicalTrials.gov ↗ ← All trials in the Netherlands